Corline Biomedical AB (CLBIO) Stock Statistics & Valuation Metrics

Corline Biomedical AB has a market cap or net worth of kr416.34M. The enterprise value is kr252.51M.

Corline Biomedical AB has 24,490,820 shares outstanding. The number of shares has decreased by -2.65% in one year.

Corline Biomedical AB’s return on equity (ROE) is -0.27 and return on invested capital (ROIC) is -26.65%.

The current PE Ratio of Corline Biomedical AB is ―. Corline Biomedical AB’s PEG ratio is -0.00712.

In the last 12 months, Corline Biomedical AB had revenue of 9.78M and earned -23.19M in profits. Earnings per share was -1.06.

In the last 12 months, operating cash flow was -16.73M and capital expenditures -460.00K, giving a free cash flow of -17.19M billion.

Corline Biomedical AB pays an annual dividend of ―, resulting in a dividend yield of ―

Corline Biomedical AB upcoming earnings date is Feb 17, 2026, TBA (Confirmed).

Corline Biomedical AB as a current ratio of 2.68, with Debt / Equity ratio of 0.00%

In the past 12 months, Corline Biomedical AB has paid 0.00 in taxes.

Corline Biomedical AB EV to EBITDA ratio is -7.54, with an EV/FCF ratio of -10.77.

Corline Biomedical AB has kr5.82M in cash and marketable securities with kr0.00 in debt, giving a net cash position of kr5.82M billion.

Gross margin is 85.82%, with operating margin of -236.99%, and net profit margin of -237.28%.

The average price target for Corline Biomedical AB is ―, which is 11.43% higher than the current price. The consensus rating is ―